ClinicalTrials.gg
Active, not recruitingNCT07393204EPKEY_HSRUpdated Feb 6, 2026

Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL

An observational study in Relapsed Diffuse Large B-cell Lymphoma (DLBCL) and Refractory Diffuse Large B-Cell Lymphoma, sponsored by Andrés José Maria Ferreri. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Andrés José Maria Ferreri · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy — 31 open to participants now, 51 under way, 12 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Italy.

Enrollment
12th of 22
150 · median 163
Started
2025
with 5 others
Observational
22 of 166
9 open now
Primary completion
2026-12
later than 17 of 50 live
Registered
160th of 166
by date

Among the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, this one is the 12th largest by enrollment of the 22 observational ones that give a count, is one of 6 that started in 2025, is one of 22 observational ones, reaches primary completion later than 17 of the 50 other live ones, and was the 160th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

31 of the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, or all of them as a file.
02

Study summary

This study describes the effectiveness of epcoritamab outside the clinical trial setting in pts with DLBCL relapsed or refractory after 2 or more previous lines of therapy

03

Conditions studied

  • Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
  • Refractory Diffuse Large B-Cell Lymphoma

Keywords

  • DLBCL
  • relapsed
  • refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study is expected to include approximately 150 patients. Patients registered in the Cnn program of epcoritamab (between February 19, 2024 and September 25, 2024) that received at least 1 dose of this antibody.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients registered in the Cnn program of epcoritamab (between February 19, 2024 and September 25, 2024)
  • Received at least one dose of epcoritamab
  • Free and voluntary written

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Patients who received epcoritamab outside the Cnn program (e.g., open access program, compassionate use, off-label, prospective trials).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
150 participants (actual)
Patient registry
No

Groups and cohorts

  • Epcoritamab treatment

    Patients registered in the Cnn program of epcoritamab (between February 19, 2024 and September 25, 2024) that received at least 1 dose of this antibody.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Overall Response Rate (ORR), defined as the best objective response achieved during or after treatment with epcoritamab, according to Lugano Criteria

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary outcomes

  1. Adverse Event according to CTCAE v5.0

    rate and severity of AEs (Adverse Event), AESIs (adverse events of special interest) and SAEs (Serious Adverse Event) according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0)

    Time frame: through study completion, an average of 1 year

  2. Incidence and Severity of Cytokine Release Syndrome (CRS)

    Incidence and Severity of Cytokine Release Syndrome (CRS) according to ASTCT CRS grading criteria

    Time frame: through study completion, an average of 1 year

  3. Incidence and Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

    ICANS graded according to ASTCT ICANS grading criteria (ICE score)

    Time frame: through study completion, an average of 1 year

  4. Complete Response rate

    CR rate defined as the proportion of patients with CR, according to Lugano Criteria at 1, 2, 3, 6, 9 and 12 months since treatment start

    Time frame: through study completion, an average of 1 year

  5. Duration of Response

    DoR is defined as the time from the first documentation of response (CR or PR) to the date of PD or death, whichever occurs earlier.

    Time frame: through study completion, an average of 1 year

  6. Duration of Complete Response

    DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs earlier.

    Time frame: through study completion, an average of 1 year

  7. Progression Free Survival

    PFS is defined as the time from the start of the treatment to first documented PD or death due to any cause, whichever occurs earlier.

    Time frame: through study completion, an average of 1 year

  8. Overall Survival

    OS is defined as the time from the start of epcoritamab treatment to death

    Time frame: through study completion, an average of 1 year

  9. Time To Next Treatment

    TTNT is defined as duration from treatment initiation to the start of new anti-lymphoma therapy or death due to PD, whichever occurs earlier

    Time frame: through study completion, an average of 1 year

  10. Duration of Treatment

    Duration of Treatment (DoT) is defined as the time from the start of the treatment to discontinuation or death due to any cause, whichever occurs earlier.

    Time frame: through study completion, an average of 1 year

  11. Health Care Resource Utilization (HCRU)

    Health Care Resource Utilization (HCRU) as number and duration of unplanned hospitalizations during treatment and follow-up, number of hematological visits, load of diagnostic exams

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Feb 6, 2026
StartActual
Dec 10, 2025
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 10, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07393204
Lead sponsor
Andrés José Maria Ferreri
Responsible party
Andrés José Maria Ferreri (Director of Lymphoma Unit, IRCCS San Raffaele) — Sponsor-investigator
First posted
Feb 6, 2026
Start date
Dec 10, 2025
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
Feb 6, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion